25 Years Ago, Medicure Was Formed

#MedicureTurns25: A conversation with our CEO, Dr. Albert Friesen as we celebrate 25 years.

The Medicure Story

2013: A new dosing strategy for AGGRASTAT

We introduced the high-dose bolus regimen for AGGRASTAT in 2013 and this became the recommended dosing for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome (NSTE-ACS). The ability of the AGGRASTAT high-dose bolus regimen to achieve >90% platelet aggregation inhibition within 10 minutes was and continues to be seen as an important feature by interventional cardiologists in settings where rapid platelet inhibition is required for coronary intervention.

2018: Majority market share

Hospital demand for AGGRASTAT continues to increase with a growing number of hospitals adding AGGRASTAT onto formulary. From initial acquisition, the patient market share increases from 2% to 65% of the GPI market.

2018: Expansion into primary care

Medicure partners with Zydus Cadila to add ZYPITAMAG (pitavastatin) tablets to its cardiovascular commercial operation. ZYPITAMAG is Medicure's first entry into the $260 billion U.S. primary care market, which includes nearly 295,000 primary care professionals.

ZYPITAMAG is a statin (HMG-CoA reductase inhibitor) medication. According to the Centers for Disease Control and Prevention (CDC), approximately one of out every three American adults have high cholesterol, putting them at increased risk for heart disease, the number 1 cause of death for Americans.

2020: Entering the online pharmacy market

Medicure enters the U.S. online pharmacy space with the acquisition of Marley Drug, Inc. Marley Drug is a leading specialty pharmacy serving more than 30,000 customers across the United States, and licensed in all 50 states, Washington D.C., and Puerto Rico.

Medicure's primary care medication, ZYPITAMAG (pitavastatin) tablets, is made available through Marley Drug, increasing access for qualifying patients who may be underinsured or uninsured with limited financial resources.

2021: MC-1 receives orphan drug and rare pediatric disease designations

Medicure receives orphan drug and rare pediatric disease designations from the FDA for its legacy product, MC-1, for the treatment of pyridox(am)ine 5'-phosphate oxidase ("PNPO") deficiency. PNPO deficiency is an inborn error of vitamin B6 metabolism, which causes an epileptic encephalopathy responsive to pyridoxal-5-phosphate (PLP).

Medicure announces pivotal Phase 3 Trial IND filing with the FDA for treatment of seizures associated with PNPO deficiency. There is an unmet need for pharmaceutical grade vitamin therapy in pyridoxine dependent epilepsies.

2021-2022: Guided by our mission

As COVID-19 swept the globe, we looked to our Mission for guidance. In the first few months, we quickly implemented remote support services for healthcare providers while ensuring supply, manufacturing, and distribution of our products were not impacted and patients would be able to receive them without interruption.

We launched a direct-to-consumer E-Commerce pharmacy platform - www.marleydrug.com, through our subsidiary, Marley Drug^® Pharmacy and expanded Marley Drug's offerings to include 100+ medications. Guided by our mission to ensure all people have access to the care they need, our acquisition of Marley Drug Pharmacy allows us to provide a solution to America's increasing prescription drug prices. An estimated 18 million Americans, or 7% of U.S. adults, could not pay for at least one drug prescribed by their doctor, according to a recent poll from Gallup and West Health.

2022: Medicure's 25th Anniversary

For 25 years, our mission has been to serve patients by delivering safe and efficacious life-changing medicines. Capitalizing on our strengths in cardiovascular therapy and knowledge of the ever changing U.S. market, we are excited to continue working towards our mission over the next 25 years. #MedicureTurns25 #WeBringMedicineToLife #AHeartForLife

25 Years Ago, Medicure Was Formed

#MedicureTurns25: A conversation with our CEO, Dr. Albert Friesen as we celebrate 25 years.

The Medicure Story

2013: A new dosing strategy for AGGRASTAT

2018: Majority market share

2018: Expansion into primary care

2020: Entering the online pharmacy market

2021: MC-1 receives orphan drug and rare pediatric disease designations

2021-2022: Guided by our mission

2022: Medicure's 25th Anniversary

Stay Connected

Sign up for our newsletter

About

Products

News and Media

Investors

Online Pharmacy

Contact Us